glp-1 drug updates Safety Check Fmr. FDA Commissioner weighs in

Exploring the potential of weight-loss drugs Previous small trials have suggested that these medications could have potential benefits for people with Parkinsons disease

Because the drugs slow down digestion, food can ferment in the stomach, leading to a build up of hydrogen sulfide

Lincoff has received consulting fees from Novo Nordisk

According to a Reuters article that inspired this blog, more than half of large employers are now signaling plans to reduce healthcare benefits in 2026 due to escalating GLP-1 and specialty drug costs

lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche Diabetes Care, and Sanofi